 | |
| Clinical data | |
|---|---|
| Other names | oMPP; oMePP; 2-Methylphenylpiperazine; 2-MPP; 2-MePP; 1-(o-Tolyl)piperazine; PAL-169 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.049.511 |
| Chemical and physical data | |
| Formula | C11H16N2 |
| Molar mass | 176.263 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ortho-Methylphenylpiperazine (also known asoMPP,oMePP,1-(2-methylphenyl)piperazine,2-MPP, and2-MePP) is apsychoactivedesigner drug of thephenylpiperazine group.[1][2] It acts as aserotonin–norepinephrine–dopamine releasing agent (SNDRA), withEC50 values for induction ofmonoaminerelease of 175 nM forserotonin, 39.1 nM fornorepinephrine, and 296–542 nM fordopamine.[3][4] As such, it has about 4.5-fold preference for induction of norepinephrine release over serotonin, and about 7.6- to 13.9-fold preference for induction of norepinephrine release over dopamine.[3][4]
The2,3-methyl and4-methylanalogues show diminished activity asdopamine releasing agents with respective EC50 values of 1,207 nM and 9,523 nM.[3][4] However, at the same time, induction of serotonin and norepinephrine release is retained and more balanced in the 2,3-methyl analogue, with respective EC50 values of 26 nM and 56 nM.[4]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |
